# Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

> **NCT01776424** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 27395 (actual)

## Conditions studied

- Prevention & Control

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Aspirin
- **DRUG:** Aspirin placebo
- **DRUG:** Rivaroxaban placebo
- **DRUG:** Pantoprazole
- **DRUG:** Pantoprazole placebo

## Key facts

- **NCT ID:** NCT01776424
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-28
- **Primary completion:** 2017-07-21
- **Final completion:** 2021-06-15
- **Target enrollment:** 27395 (ACTUAL)
- **Last updated:** 2022-11-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01776424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01776424, "Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01776424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*